Sarepta hit by new short attack; general biotech selloff Clinical trial data for eteplirsen not enough for early/accelerated FDA approval is among the claims of research shop Favus in what Adam Feuerstein calls a "rehash of old short arguments." Sarepta Therapeutics ( SRPT -8.4% ). Not helping is a second straight day of big declines for momentum names in general and biotech stocks in particular . Post your comment!
Oct. 9, 2013 - Seeking Alpha